Want to see LH full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.Recent quarters show rising amortization—consistent with Labcorp’s active M&A and capitalized intangibles—while the very large impairments in late 2022–2023 appear to be largely nonrecurring, clearing the deck for margin improvement. SG&A has settled higher than pre‑pandemic levels, reflecting targeted investments (AI, product launches) that management points to as drivers of expanded adjusted margins and raised EPS guidance. That said, sporadic restructuring spikes (notably the 2025‑Q4 charge) remind investors integration and strategic actions can materially dent near‑term earnings and cash flow, so monitor FCF and leverage.
Date | Selling, General, and Administrative | Restructuring and Other | Impairments | Amortization |
|---|---|---|---|---|
Jun 30, 2026 | $577.20M | $5.10M | $0.00 | $78.10M |
Mar 31, 2026 | $551.00M | $6.40M | $0.00 | $75.60M |
Dec 31, 2025 | $538.60M | $110.80M | $3.60M | $72.60M |
Sep 30, 2025 | $552.40M | $5.90M | $700.00K | $69.50M |
Jun 30, 2025 | $579.30M | $4.10M | $0.00 | $68.30M |
Mar 31, 2025 | $546.00M | $6.40M | $0.00 | $69.60M |
Dec 31, 2024 | $595.20M | $11.40M | $2.80M | $70.40M |
Sep 30, 2024 | $568.60M | $18.00M | $0.00 | $63.70M |
Jun 30, 2024 | $557.80M | $11.60M | $0.00 | $62.20M |
Mar 31, 2024 | $508.40M | $5.00M | $2.50M | $60.10M |